Further inspection of the MSigDB16,17 showed that 36% of genes adjacent to or inside the top 2000 cancer-specific markers are involved in known cancer modules, and 44% of those are part of oncogenic signatures that are activated in cancer cells upon perturbation in KRAS, PRC2, and TP53. This evidence concerns the gene KRAS and cancer.